Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MRC AGHRB - MR/Y019717/1 | Other Grant/Funding Number | MRC-UKRI (MRC and the International Science Partnerships Fund (ISPF)) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical Research Council | OTHER_GOV |
| Infectious Diseases Institute, Uganda | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn if the intervention of delivery of antiretroviral drugs by medical drones can improve virological suppression in a fisherfolk community population living with HIV in the islands of Kalangala District, Uganda. The main question it aims to answer is:
Can delivery of anti-retroviral therapy (ART) by unmanned aerial vehicles (medical drones) to people living with HIV (PLHIV) improve virological outcomes compared to the standard of care (SOC) in an underserved population? Primary hypothesis: The investigators hypothesize that using drones will increase viral suppression in those receiving the intervention as compared to the control or outcome measure one-will be the proportion of PLHIV with undetectable HIV viral load in the intervention (drones) versus SOC arm at 12 months.
If there is a comparison group: Researchers will compare [Medical Drones delivery group] to see total cost of 12 months medication delivery to people living with HIV (PLHIV) in the intervention as compared to standard of care (SOC) arm.
Proportion PLHIV with an undetectable viral load at 6, 18 and 24 months in intervention Rates of retention in care of PLHIV at 6,12, 18 and 24 months in intervention as compared to SOC arm
The Investigators will undertake a cluster randomised trial of the efficacy of medical drone use by randomization of health facilities and their associated landing sites in Kalangala District. There are 64 landing sites and 18 health facilities. The unit of radomisation will be the landing site, so that all persons at one landing site will receive the drone delivery or boat delivery, facility pick-up. This will avoid contamination of drone delivery by sharing of ART between people getting drone and boat or other modes of deliveries. Bias in this situation will be managed by stratifying the landing sites by distance from drone operations base (a proxy of delivery cost), and number of differentiated service delivery (DSD) groups. Bias in gender and age will be managed at selection of members in DSD groups. We will also undertake a cost effectiveness analysis, carbon analysis and process evaluation. A qualitative study will assess acceptability and additional use cases
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Arm | Experimental | Delivery of ART by fixed wing drones to landing sites |
|
| Control arm | Active Comparator | Usual ART delivery to landing sites |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Drone delivery | Device | Usual ART delivery to landing sites |
| |
| Measure | Description | Time Frame |
|---|---|---|
| primary endpoint is the proportion of participants with HIV RNA viral load < 200 copies/mL at 12 months | Analysis of the primary endpoint shall be done on modified intention-to-treat population, mITT (i.e. includes all participants randomized, and received at-least one dose of treatment). We shall use log-binomial/Poisson mixed effects regression model to compare proportion of PLHIV with an undetectable HIV viral load (i.e. <200 copies/mL) at month 12 between the two arms | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Intermediate and final 12-month retention in care in those receiving ART via drone compared to control population | Retention in care defined as participant with a facility or ART encounter for > 90 days after the last missed scheduled ART collection | 12 months |
| proportion of viral load > 200 copies/mL at 24 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rosalind Principal Investigator, MBBS, MA Hons, MRCP, Ph.D | Contact | +256312211422 | rratanshi@idi.co.ug | |
| Agnes Bwanika Naggirinya, MBChB, MSC, MMed | Contact | +256 312211422 | anaggirinya@idi.co.ug |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bwendero Health Centre | Recruiting | Kalangala | Ssese | Uganda |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
De-identified individual participant data collected during the trial will be shared at the end of the project after manuscript have been completed.
Start dates 2027 No limit/end
All interested researchers, policy makers, participants. Can access the data sets, clinical reports, monitoring reports, DSMB reports
Not provided
Cluster randomised trial using a non-inferiority design
Not provided
Not provided
Not provided
Not provided
| Fixed Wing drones |
| Device |
Last Mile fixed wing drone delivery |
|
Proportions be summarised by the treatment arms and compared used Pearson Chi-square test. |
| 24 months |
| Mugoye health Centre III | Recruiting | Kalangala | Ssese | Uganda |
|